Awaiting development: Guidance and quality standards
Showing 291 to 294 of 294
| Title | Type |
|---|---|
| Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040] | Technology appraisal guidance |
| Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573] | Technology appraisal guidance |